Trial Profile
The effect and resistant mechanisms to afatinib followed by osmertinib in T790M-Mutant non small cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2018
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer